Eldecalcitol replaces endogenous calcitriol but does not fully compensate for its action in vivo

Journal of Steroid Biochemistry and Molecular Biology

Volumn 144, Issue PART A, 2014, Pages 189-196

  Saito, Hitoshi ^a   Harada, Suguru ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Calcium; Eldecalcitol; Phosphorus; VDR

Indexed keywords

CALBINDIN 1; CALCITRIOL; ELDECALCITOL; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHORUS; VANILLOID RECEPTOR 5; VANILLOID RECEPTOR 6; VITAMIN D RECEPTOR; CALCIUM; COLECALCIFEROL 24 HYDROXYLASE; CYTOCHROME P450; CYTOCHROME P450 27B1; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; BIOLOGICAL ACTIVITY; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCIUM URINE LEVEL; CONTROLLED STUDY; CORRELATIONAL STUDY; GENE EXPRESSION; GENE INACTIVATION; GENE TARGETING; IN VIVO STUDY; KNOCKOUT MOUSE; LIMIT OF DETECTION; MALE; MOUSE; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; REVIEW; ANIMAL TISSUE; ARTICLE; CALCIUM METABOLISM; COMPARATIVE STUDY; DRUG BLOOD LEVEL; PHOSPHATE METABOLISM; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

MUS; RATTUS;

CALCIUM; ELDECALCITOL; PHOSPHORUS; VDR;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; GENE EXPRESSION REGULATION; HUMANS; MICE; RATS; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 84906791135     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2013.11.013     Document Type: Review

References (26)

1. R. Bouillon, G. Carmeliet, L. Verlinden, E. van Etten, A. Verstuyf, H.F. Luderer, L. Lieben, C. Mathieu, and M. Demay Vitamin D and human health: lessons from vitamin D receptor null mice Endocr. Rev. 29 6 2008 726 776
2. M.R. Walters Newly identified actions of the vitamin D endocrine system Endocr. Rev. 13 4 1992 719 764
3. R. Bouillon, W.H. Okamura, and A.W. Norman Structure-function relationships in the vitamin D endocrine system Endocr. Rev. 16 2 1995 200 257
4. H.L. Brenza, C. Kimmel-Jehan, F. Jehan, T. Shinki, S. Wakino, H. Anazawa, T. Suda, and H.F. DeLuca Parathyroid hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter Proc. Natl. Acad. Sci. U.S.A. 95 4 1998 1387 1391
5. 2D3 Biochem. Biophys. Res. Commun. 249 1 1998 11 16
6. 2D3 in intact animals Endocrinology 140 5 1999 2224 2231
7. T. Shimada, M. Kakitani, Y. Yamazaki, H. Hasegawa, Y. Takeuchi, T. Fujita, S. Fukumoto, K. Tomizuka, and T. Yamashita Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism J. Clin. Invest. 113 4 2004 561 568
8. M.R. Haussler, G.K. Whitfield, C.A. Haussler, J.C. Hsieh, P.D. Thompson, S.H. Selznick, C.E. Dominguez, and P.W. Jurutka The nuclear vitamin D receptor: biological and molecular regulatory properties revealed J. Bone Miner. Res. 13 3 1998 325 349
9. S. Kato The function of vitamin D receptor in vitamin D action J. Biochem. 127 5 2000 717 722
10. S. Christakos, P. Dhawan, Y. Liu, X. Peng, and A. Porta New insights into the mechanisms of vitamin D action J. Cell Biochem. 88 4 2003 695 705
11. T. Yoshizawa, Y. Handa, Y. Uematsu, S. Takeda, K. Sekine, Y. Yoshihara, T. Kawakami, K. Arioka, H. Sato, Y. Uchiyama, S. Masushige, A. Fukamizu, T. Matsumoto, and S. Kato Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning Nat. Genet. 16 4 1997 391 396
12. P.J. Malloy, J.W. Pike, and D. Feldman The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets Endocr. Rev. 20 2 1999 156 188
13. N. Yagishita, Y. Yamamoto, T. Yoshizawa, K. Sekine, Y. Uematsu, H. Murayama, Y. Nagai, W. Krezel, P. Chambon, T. Matsumoto, and S. Kato Aberrant growth plate development in VDR/RXR gamma double null mutant mice Endocrinology 142 12 2001 5332 5341
14. S. Christakos Recent advances in our understanding of 1,25-dihydroxyvitamin D(3) regulation of intestinal calcium absorption Arch. Biochem. Biophys. 523 1 2012 73 76
15. T. Matsumoto, M. Ito, Y. Hayashi, T. Hirota, Y. Tanigawara, T. Sone, M. Fukunaga, M. Shiraki, and T. Nakamura A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures - a randomized, active comparator, double-blind study Bone 49 4 2011 605 612
16. T. Matsumoto, T. Takano, S. Yamakido, F. Takahashi, and N. Tsuji Comparison of the effects of eldecalcitol and alfacalcidol on bone and calcium metabolism J. Steroid Biochem. Mol. Biol. 121 1-2 2010 261 264
17. H. Tsurukami, T. Nakamura, K. Suzuki, K. Sato, Y. Higuchi, and Y. Nishii A novel synthetic vitamin D analogue, 2 beta-(3-hydroxypropoxy)1 alpha, 25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats Calcif. Tissue Int. 54 2 1994 142 149
18. Y. Tanaka, T. Nakamura, S. Nishida, K. Suzuki, S. Takeda, K. Sato, and Y. Nishii Effects of a synthetic vitamin D analog, ED-71, on bone dynamics and strength in cancellous and cortical bone in prednisolone-treated rats J. Bone Miner. Res. 11 3 1996 325 336
19. Y. Uchiyama, Y. Higuchi, S. Takeda, T. Masaki, A. Shira-Ishi, K. Sato, N. Kubodera, K. Ikeda, and E. Ogata ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis Bone 30 4 2002 582 588
20. T. Matsumoto, and N. Kubodera ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects J. Steroid Biochem. Mol. Biol. 103 3-5 2007 584 586
21. S. Takeda, S. Sakai, A. Shiraishi, N. Koike, M. Mihara, and K. Endo Combination treatment with eldecalcitol (ED-71) and raloxifene improves bone mechanical strength by suppressing bone turnover and increasing bone mineral density in ovariectomized rats Bone 53 1 2013 167 173
22. A.J. Brown, and C.S. Ritter The vitamin D analog 1alpha,25-dihydroxy- 2beta-(3-hydroxypropyloxy) vitamin D(3) (eldecalcitol) is a potent regulator of calcium and phosphate metabolism Calcif. Tissue Int. 89 5 2011 372 378
23. T. Okano, N. Tsugawa, S. Masuda, A. Takeuchi, T. Kobayashi, Y. Takita, and Y. Nishii Regulatory activities of 2 beta-(3-hydroxypropoxy)-1 alpha, 25-dihydroxyvitamin D3, a novel synthetic vitamin D3 derivative, on calcium metabolism Biochem. Biophys. Res. Commun. 163 3 1989 1444 1449
24. 3 and its analogs Life Sci. 62 5 1998 453 459
25. C.S. Ritter, and A.J. Brown Suppression of PTH by the vitamin D analog eldecalcitol is modulated by its high affinity for the serum vitamin D-binding protein and resistance to metabolism J. Cell Biochem. 112 2011 1348 1352
26. K. Miyamoto, E. Murayama, K. Ochi, H. Watanabe, and N. Kubodera Synthetic studies of vitamin D analogues. XIV. Synthesis and calcium regulating activity of vitamin D3 analogues bearing a hydroxyalkoxy group at the 2 beta-position Chem. Pharm. Bull. (Tokyo) 41 6 1993 1111 1113